HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion.

AbstractBACKGROUND:
Platelet (PLT) and plasma transfusion remain the mainstay hemostatic therapy for perioperative bleeding. Several studies have indicated that acquired fibrinogen (FIB) deficiency can be the primary cause of bleeding after cardiac surgery. The aim of this study was to compare hematologic and transfusion profiles between the first-line FIB replacement and PLT transfusion in post-cardiac surgical bleeding.
STUDY DESIGN AND METHODS:
In this prospective, randomized, open-label study, 20 adult patients who underwent valve replacement or repair and fulfilled preset visual bleeding scale were randomized to 4 g of FIB or 1 unit of apheresis PLTs. Primary endpoints included hemostatic condition in the surgical field and 24-hour hemostatic product usage. Hematologic data, clinical outcome, and safety data were collected up to the 28th day postoperative visit.
RESULTS:
In patients who received the first-line FIB concentrate (n = 10), the visual bleeding scale improved after intervention, and the incidence of PLT transfusion and total plasma donor exposure were lower compared to the PLT group (n = 10). Postintervention FIB level was statistically higher (209 mg/dL vs. 165 mg/dL) in the FIB group than in the PLT group, but PLT count and prothrombin were lower. There were no statistical differences in the postoperative blood loss and red blood cell transfusion between two groups.
CONCLUSIONS:
Our preliminary data indicate that the primary FIB replacement may potentially reduce the incidence of PLT transfusion and the number of donor exposures. Plasma FIB level of 200 mg/dL is attainable with a single dose of 4 g, and this level seems to mitigate bleeding despite moderately decreased thrombin generation.
AuthorsKenichi A Tanaka, Katherine Egan, Fania Szlam, Satoru Ogawa, John D Roback, Gautam Sreeram, Robert A Guyton, Edward P Chen
JournalTransfusion (Transfusion) Vol. 54 Issue 1 Pg. 109-18 (Jan 2014) ISSN: 1537-2995 [Electronic] United States
PMID23718572 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Copyright© 2013 American Association of Blood Banks.
Chemical References
  • Coagulants
  • Fibrinogen
Topics
  • Adult
  • Aged
  • Cardiac Valve Annuloplasty (adverse effects)
  • Coagulants (administration & dosage, adverse effects)
  • Female
  • Fibrinogen (administration & dosage, adverse effects)
  • Freeze Drying
  • Humans
  • Length of Stay (statistics & numerical data)
  • Male
  • Middle Aged
  • Platelet Transfusion (adverse effects, methods)
  • Postoperative Hemorrhage (epidemiology, etiology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: